Annolyse
BriefingsCompaniesScreenerInsightsPrinciplesCompareChatWatchlist

Explore

  • Briefings
  • Companies
  • Screener
  • Insights
  • Compare

Resources

  • Search
  • Methodology

© 2026 Annolyse.

ChartsAnalysisChatData
  1. Charts
  2. Valuation
  3. Analysis
  4. Chat
  5. Data
  6. Sources
←Back to briefings
Iperion (IPR) / HY25

Loss narrowed 21.4% but equity fell 62.2% on continued zero-revenue burn

The smaller HY25 loss is cost-base contraction, not progress, with NZ$0.1m of cash facing a NZ$0.3m half-year operating burn.

Construction & Materials / Critical minerals

IPR revenue trajectory

Revenue context before the current result.

↗
Loading chart...
FY24 was $0m, versus $0.03m in FY23.

IPR operating cash flow

Operating cash flow across covered periods.

↗
Loading chart...
FY24 was -$0.73m, versus -$0.41m in FY23.

IPR NPAT trajectory

Statutory profit after tax across covered periods.

↗
Loading chart...
FY24 was -$0.8m, versus -$0.3m in FY23.

IPR ROE

Return on equity across covered periods.

↗
Loading chart...
FY24 was -0.1%, versus -17.2% in FY23.

Market context

Valuation

A close-dated read on what the market price implies next to the latest verified filing inputs. Unavailable metrics stay visible when the absence is useful context.

Prices as at close, 12 June 2026

Price and market cap

The latest close and share count context for the market price.

Market cap

$1.5m

i

End-of-day close multiplied by current shares on issue.

Profitability multiples

How the market price compares with recent earnings and cash-flow inputs.

P/E

Not available

i

Not meaningful when recent earnings are negative.

EPS

-0.00

i

Recent filing-derived earnings per share.

PEG

Not available

i

Not available for this company right now.

EV/EBITDA

Not available

i

Not meaningful when recent EBITDA is negative.

P/FCF

Not available

i

Not meaningful when free cash flow is negative or unavailable.

P/B

28.61x

i

Market value compared with latest reported equity.

Income and fund shape

Yield and fund-style valuation where the company shape supports it.

Dividend yield

0.0%

i

Trailing dividends compared with the latest close.

Total return

Not available

i

Available once dividend and adjustment data are verified.

Release date
28 November 2024
Published
28 April 2026
Ask about this result
Sections⌄
  1. Charts
  2. Valuation
  3. Analysis
  4. Chat
  5. Data
  6. Sources

Key metrics

Numbers worth scanning first

HY25 vs HY24

Revenue

$0m

flat vs $0m

Net profit after tax

−$0.4m

+20.0% ↑ vs −$0.5m

Net cash inflow from operating activities

−$0.27m

+27.8% ↑ vs −$0.37m

Profit before tax

−$0.4m

+20.0% ↑ vs −$0.5m

Total assets

$0.62m

-50.9% ↓ vs $1.3m

What changed

The economically material movement is balance-sheet erosion rather than the narrower loss

Total equity fell 62.2% to NZ$0.4m and total assets fell 50.9% to NZ$0.6m versus the prior balance date, while total liabilities rose 80% to NZ$0.2m. Annolyse's historical baseline classifies the current asset base as the lower edge of the supplied range (mean NZ$1.3b, range NZ$0.3m–NZ$2.1b), reflecting a structurally smaller entity than the longer-run history.

Revenue was nil in both halves, unchanged at 0.0%. The reported loss narrowed: NPAT was a NZ$0.4m loss versus NZ$0.5m, a 21.4% improvement, and PBT moved by the same 21.4% because no tax has been booked in either period. Operating cash outflow improved to NZ$0.3m from NZ$0.4m. Closing cash sat at NZ$0.1m versus effectively nil at the prior comparable.

What matters

Going-concern arithmetic dominates the read

Closing cash of NZ$0.087m sits against a half-year operating outflow of NZ$0.268m. On a straight-line read, the cash on hand covers roughly two months of the current burn, so the result is functionally a runway disclosure rather than an earnings update. This matters because any continued operation requires either a near-term capital raise, expense reduction below the current run-rate, or a path to revenue not evidenced in this filing.

Equity declined by more than the reported loss. Total equity fell NZ$0.7m over the half while NPAT recorded a NZ$0.4m loss, leaving roughly NZ$0.3m of equity movement not explained by the income statement in the extracted disclosures. For a NZ$0.4m equity base, an unexplained gap of that scale is material to anyone trying to understand the true cash and reserves position.

The 21.4% loss improvement is cost contraction, not commercial progress. With zero revenue in both periods and Annolyse's historical baseline showing PBT growth at the upper edge of a -249.5% to 56.6% range, the headline improvement is the company spending less on a non-operating cost base. It does not indicate movement toward commercialisation.

Expectations

No forward target, guidance, or forward-work figure has been supplied

The available shape context is HY24's 57% share of FY24 NPAT, which implied a second-half loss of NZ$0.3m and a full-year NZ$0.7m loss. If the cost base behaves similarly into 2H25, full-year cash burn would again exceed available cash by a wide margin without external funding.

The prior-comparable release referenced pursuit of manufacturing and product certifications and a path to commercial production. The current release contains no equivalent commercial-progress narrative in the supplied excerpts, so the filing does not support an inference that revenue is imminent. The gap between cash on hand and forecastable burn is the dominant near-term issue.

Quality of result

Standard earnings-quality framing has limited traction here

With no revenue, no EBITDA disclosed, and no working-capital cycle to assess, the result is essentially the difference between two cost-base periods. Current FCF-to-NPAT of 74.5% reflects the small scale of accruals rather than durable cash generation. The improvement in operating cash outflow tracks the improvement in the reported loss and is consistent with cost-base contraction.

The more pertinent quality question concerns the balance sheet. Total liabilities rising 80% on a tiny base is mechanically small (NZ$0.08m) but matters because it offsets some of the cash held. The unexplained portion of the equity decline is the largest quality flag: in a company this size, NZ$0.3m of unreconciled equity movement materially affects the read on what is left to fund operations. Until that is reconciled, the durability of the disclosed equity figure should be treated as provisional.

Unresolved

Open questions

What explains the NZ$0.3m gap between the NZ$0.7m decline in equity and the NZ$0.4m reported NPAT loss over the half?
How does management intend to fund operations given NZ$0.087m of cash against an NZ$0.268m half-year operating outflow?
Why has total liabilities risen 80%, and what are the components on a NZ$0.2m liability balance?
What is the current status of the manufacturing and product certifications referenced in the prior comparable, and is any sales pipeline contracted?
Will the board seek shareholder approval for a capital raise, and on what timetable?

This briefing cannot assess solvency, share-issuance plans, or the company's contractual obligations without the full notes to the interim accounts and any subsequent capital-management disclosures.

Chat

Ask about IPR HY25

Ask follow-up questions about Iperion's HY25 result.

Informational only. No buy, sell, hold, price-target, or personal financial advice.

Ask about IPR HY25

Informational only. No buy, sell, hold, price-target, or personal financial advice.

Sign in to chat

Sign in to ask questions about Iperion's HY25 result.

What explains the NZ$0.3m gap between the NZ$0.7m decline in equity and the NZ$0.4m reported NPAT loss over the half?Why does "Going-concern arithmetic dominates the read" matter?How strong was the cash and earnings quality in HY25?What should I watch next for IPR after HY25?

Checking account...

Data appendix

Show analytical metrics

Open to load analytical metrics.

Show key metrics table

Open to load key metrics.

Sources

Current period

IPR 1H25 Interim Report Sep24

HY25 / financial report↗

IPR 1H25 NZX Result Template

HY25 / results announcement↗

IPR 1H25 NZX Result Template

HY25 / results release↗

Prior comparable period

IPR 1H24 Interim Report

HY24 / financial report↗

IPR 1H24 NZX Results Template

HY24 / results announcement↗

IPR 1H24 NZX Results Template

HY24 / results release↗

Full-year context

IPR 2024 Preliminary Full Year Result (Unaudited)

FY24 / financial report↗

Release context

2024 Annual Meeting result

HY25 / commentary↗

Related insights

Cross-company views selected from the metrics in this briefing.

Earnings quality and statutory distortions

PBT and NPAT growth diverged by 0.0pp.

→

Revenue growth context

Revenue growth was 0.0% for this reporting period.

→
This briefing is based on available company filings and standard Annolyse calculations. It is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.

Get notified when IPR publishes next

Get the next Iperion briefing and related NZX reporting-season updates by email.